Investment
Features
FeesSafety
Academy
More
Pluang+

Amgen expects 2.9% revenue growth but 7% earnings decline in Q2 2026 amid strong drug sales.

Company Fundamentals
04 Aug 2026
Gordon Thompson
View Source
Bullish
pluang ai news

Amgen is set to report its Q2 2026 earnings with analysts forecasting a 2.9% increase in revenue to about $9.45 billion, despite a projected 7% drop in earnings to $5.60 per share. The company benefits from strong sales of key drugs like Repatha, Tezspire, and Evenity, which helped it exceed last quarter's earnings expectations by 8.88%. Investors are closely watching updates on the MariTide obesity drug candidate and biosimilar product sales. Valuation metrics show a Price-to-Earnings ratio of 26.47 and a Debt-to-Equity ratio of 6.24, indicating how the company is priced and financed amid competitive pressures.

More News (AMGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App